An annual screening for breast cancer using a combination of MRI and mammography could be an effective program for high-risk women, particularly those who are known BRCA mutation carriers.
Computer software used to help decipher screening mammograms reduces interpretation accuracy, increases the rate of unnecessary biopsies, and offers no clear improvement in the detection of invasive breast cancer, the largest and most comprehensive community-based study of the technology has found.
A computerized mail and phone reminder program managed by appointment secretaries significantly increased the percentage of patients undergoing annual mammography at the Mayo Clinic
Magnetic resonance imaging (MRI) of the contralateral breast in 969 women newly diagnosed with cancer in one breast detected 30 (3.1%) contralateral breast cancers that were missed by mammography and clinical breast exam at the time of diagnosis.
A mobile mammography unit that links a digital mammography system with a commercial satellite service provides near real-time interpretation of breast imaging scans to Native American women on remote rural reservations
A random sampling of 2.3% of the imaging centers that meet Mammography Quality Standards Act (MQSA) certification showed that the national median cash price for a screening mammogram is more than double the price that is reimbursed by Medicare.
New subgroup analyses from the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group confirm previous results that digital screening mammography is significantly more accurate than film screening mammography in young women with dense breasts but not in women overall.
Black Women Urged to Have Screening Mammograms, and Genetic Testing for Those With Strong Family History
White women have
a higher incidence of breast cancer than
African-American women, but African-
American women develop the disease at
a younger age, are diagnosed later, and
are more likely to die of the disease, according
to the National Cancer Institute.
Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS).
Nine weeks of trastuzumab (Herceptin) given concurrently with single-agent docetaxel (Taxotere) or vinorelbine (Navelbine) prior to combination chemotherapy improves survival in HER2-positive breast cancer patients, compared with no trastuzumab, with the docetaxel regimen having a slight advantage over vinorelbine.